In conclusion, our study underscores the critical role of MALAT1 in tamoxifen resistance and provides strong evidence that NanoCurcumin can serve as an effective modulator of MALAT1 expression, potentially reversing or preventing endocrine therapy resistance in ER+ breast cancer. The gene discussed is MALAT1; the disease is breast carcinoma.